New approaches in nuclear medicine theranostics

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Development
• Theranostics

Background:

• Recent advancements in Nuclear Medicine driven by successful radioligands.
• Significant industry investment in the radiopharmaceutical market.
• Development of innovative theranostic agents is ongoing.

Purpose of the Study:

• To review four promising novel theranostic approaches in Nuclear Medicine.
• To highlight agents with potential for increased importance in patient care.
• To showcase the diversity of current radiopharmaceutical development.

Main Methods:

• Focus on radiopharmaceuticals targeting specific molecular targets.
• Review of agents currently in clinical trials or the clinical arena.
• Discussion of four distinct therapeutic and diagnostic approaches.

Main Results:

• Fibroblast activation protein is a leading target with numerous clinical trials.
• Other promising agents targeting carbonic anhydrase IX, C-X-C motif chemokine receptor 4, estrogen receptors, and somatostatin receptor 2 are emerging.
• These agents represent diverse applications within Nuclear Medicine.

Conclusions:

• The reviewed radiopharmaceuticals are poised to significantly impact future patient care.
• Continued innovation in theranostic agents is expanding treatment options.
• Nuclear Medicine offers a broad spectrum of evolving diagnostic and therapeutic tools.